Lincoln Pharmaceuticals Limited
Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It … Read more
Lincoln Pharmaceuticals Limited (LINCOLN) - Total Assets
Latest total assets as of September 2025: ₹8.55 Billion INR
Based on the latest financial reports, Lincoln Pharmaceuticals Limited (LINCOLN) holds total assets worth ₹8.55 Billion INR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lincoln Pharmaceuticals Limited - Total Assets Trend (2006–2025)
This chart illustrates how Lincoln Pharmaceuticals Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Lincoln Pharmaceuticals Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Lincoln Pharmaceuticals Limited's total assets of ₹8.55 Billion consist of 62.7% current assets and 37.3% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹90.17 Million | 1.7% |
| Accounts Receivable | ₹2.02 Billion | 25.3% |
| Inventory | ₹786.77 Million | 9.9% |
| Property, Plant & Equipment | ₹1.86 Billion | 23.3% |
| Intangible Assets | ₹4.40 Million | 0.1% |
| Goodwill | ₹0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Lincoln Pharmaceuticals Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lincoln Pharmaceuticals Limited's current assets represent 62.7% of total assets in 2025, a decrease from 84.2% in 2006.
- Cash Position: Cash and equivalents constituted 1.7% of total assets in 2025, down from 2.1% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 25.3% of total assets.
Lincoln Pharmaceuticals Limited Competitors by Total Assets
Key competitors of Lincoln Pharmaceuticals Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Lincoln Pharmaceuticals Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Lincoln Pharmaceuticals Limited generates 0.78x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Lincoln Pharmaceuticals Limited generates $ 10.33 in net profit.
Lincoln Pharmaceuticals Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.71 | 4.34 | 3.51 |
| Quick Ratio | 4.01 | 3.64 | 3.05 |
| Cash Ratio | 0.02 | 0.19 | 0.00 |
| Working Capital | ₹4.30 Billion | ₹ 4.03 Billion | ₹ 2.22 Billion |
Lincoln Pharmaceuticals Limited - Advanced Valuation Insights
This section examines the relationship between Lincoln Pharmaceuticals Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.73 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 13.8% |
| Total Assets | ₹7.97 Billion |
| Market Capitalization | $62.93 Million USD |
Valuation Analysis
Below Book Valuation: The market values Lincoln Pharmaceuticals Limited's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Lincoln Pharmaceuticals Limited's assets grew by 13.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Lincoln Pharmaceuticals Limited (2006–2025)
The table below shows the annual total assets of Lincoln Pharmaceuticals Limited from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹7.97 Billion | +13.81% |
| 2024-03-31 | ₹7.00 Billion | +19.21% |
| 2023-03-31 | ₹5.87 Billion | +9.93% |
| 2022-03-31 | ₹5.34 Billion | +18.13% |
| 2021-03-31 | ₹4.52 Billion | +16.17% |
| 2020-03-31 | ₹3.89 Billion | +6.61% |
| 2019-03-31 | ₹3.65 Billion | +5.19% |
| 2018-03-31 | ₹3.47 Billion | +13.72% |
| 2017-03-31 | ₹3.05 Billion | +10.74% |
| 2016-03-31 | ₹2.76 Billion | +6.86% |
| 2015-03-31 | ₹2.58 Billion | -0.66% |
| 2014-03-31 | ₹2.60 Billion | +9.66% |
| 2013-03-31 | ₹2.37 Billion | +10.09% |
| 2012-03-31 | ₹2.15 Billion | +33.85% |
| 2011-03-31 | ₹1.61 Billion | +44.92% |
| 2010-03-31 | ₹1.11 Billion | +51.90% |
| 2009-03-31 | ₹730.30 Million | +19.62% |
| 2008-03-31 | ₹610.52 Million | +10.70% |
| 2007-03-31 | ₹551.50 Million | +5.95% |
| 2006-03-31 | ₹520.52 Million | -- |